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1. Introduction 
The progression of nanotechnology has produced engineered fine nanoparticles for use in 
biomedical applications. Drug delivery systems are in a particularly promising field for the use 
of the unique properties of nanoparticles in biomedical applications. The pharmacokinetics of 
nanoparticles differs considerably from that of small drug molecules. Therefore, a drug 
delivery system based on nanoparticles offers a novel direction of drug discovery as well as an 
improved delivery system for use with conventional drugs. It has been demonstrated that 
drug delivery systems using nanoparticles are advantageous for stable solubilization of 
lipophilic drugs, reduced toxicity, inhibition of enzymatic degradation of the drugs, and so on 
(Moghimi et al., 2001; Papahadjopoulos et al., 1991; Torchilin, 2005). Nanoparticulate drugs 
show longer circulation time by avoiding renal excretion compared to drugs with small 
molecules. Moreover, one important technology termed "PEGylation", surface modification of 
nanoparticles by polyethylene glycol (PEG) chains, prolonged the circulation time (Klibanov et 
al., 1990; Owens & Peppas, 2006). These long-circulating nanoparticles are effective to increase 
the passive delivery of anticancer drugs into tumor tissues having leaky blood capillaries with 
wide fenestrations (Matsumura & Maeda, 1986; Gabizon et al., 1994). 
Practical nanotechnology and methodologies to target a specific organ or cell actively are of 
current interest in the development of further advanced drug delivery systems. For this 
purpose, the specific interaction which is typically mediated by the receptors on a cell surface 
must be ascertained. Furthermore, non-specific interactions must be minimized to achieve 
high selectivity to the target. These specific and selective mechanisms are working constantly 
in communication, transport, and metabolism processes in living system. Drug carriers offer a 
platform to target these biological mechanisms. Several results of studies have shown that the 
bone marrow is the principal organ for the specific uptake of bioparticles such as senescent 
cells, lipoproteins, and nuclei from erythroid precursor cells through the mononuclear 
phagocyte system (Hussain et al., 1989a; Qiu et al., 1995; Rankin, 2010). This importance 
suggests that the phagocytic activity of bone marrow is a potent target of nanoparticle-based 
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drug delivery. In fact, it has been demonstrated that nanoparticles modified with a specific 
molecule on their surface are distributed selectively into bone marrow tissues (Harris et al. 
2010; Mann et al., 2011; Moghimi, 1995; Porter et al., 1992; Schettini et al., 2006; Sou et al. 2007, 
2010, 2011a). These bone marrow-specific drug carrier systems are expected to improve 
diagnostic and therapeutic systems to treat hematopoietic disorders. This chapter presents a 
review of the specific targeting of bone marrow using nanoparticles as carriers. Furthermore, 
future aspects of their medical applications are discussed. 
2. Functions of bone marrow for blood cell turnover 
Bone marrow, a soft and spongy tissue found in the hollow spaces in the interior of bones, 
constitutes about 4% of the total body weight of adult humans. Progenitor cell (stem cell) 
lines in the bone marrow produce new blood cells and stromal cells. It has been estimated 
that as many as 4.9 × 1011 senescent blood cells are eliminated from blood circulation per day 
in adult humans (Fliedner et al., 1976, 2002). Figure 1 shows that almost as many blood cells 
are released from bone marrow to maintain a constant number of circulating blood cells. 
Bone marrow possesses an efficient system that takes nutrients from blood circulation 
selectively for blood cell production. 
Mononuclear phagocyte systems in liver and spleen have been regarded as the main pathway 
to eliminate senescent blood cells. However, a recent study has shown that mouse bone marrow 
is an important organ for eliminating white blood cells, especially neutrophils, where 
neutrophils are ultimately phagocytosed by bone marrow stromal macrophages (Dalli et al., 
2012; Furze & Rankin, 2008; Rankin, 2010). The expression of the anti-inflammatory molecule 
annexin A1 by resident macrophages is necessary for clearance of senescent neutrophils, which 
are determined by their higher levels of CXCR4 expression and annexin V binding in the mouse 
bone marrow (Dalli et al., 2012). Consequently, it can be speculated that annexin A1 on bone 
marrow resident macrophages specifically interacts with senescent neutrophils. High uptake of 
white blood cells in bone marrow can also be observed in humans following administration of 
111In-radiolabeled white blood cells that are administered routinely to humans for the detection 
of occult infection which is first recognized by secondary manifestations such as increased 
neutrophils in the circulation or fever of unknown origin. Whole body region-of-interest 
analysis frequently reveals that 60–70% of the administered white blood cells localize to bone 
marrow, whereas 30–40% localize to liver and spleen (Sou et al., 2011a). 
Chylomicrons are large lipoprotein particles that consist of triglycerides, phospholipids, 
cholesterol, and proteins. Hussain and co-workers reported that rabbit and marmoset bone 
marrow had significant uptake of chylomicrons labeled with [14C] cholesterol and [3H] 
retinol (Hussain et al., 1989b). Perisinusoidal macrophages protruding through the 
endothelial cells into the marrow sinuses were responsible for accumulation of the 
chylomicrons in the marmoset bone marrow. In contrast to marmosets, chylomicron 
clearance from the bone marrow of rats, guinea pigs, and dogs was much less, and the 
spleen in rats and guinea pigs took up a large fraction of chylomicrons. Consequently, 
Hussain et al. concluded that the observed differences in chylomicron metabolism result 
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from the presence of perisinusoidal macrophages in bone marrow. It was also believed that 
the differences between bone marrow and spleen uptake of chylomicrons might provide 
insights into the role of chylomicron catabolism in these organs, both of which are involved 
in hematopoiesis. It was speculated that the chylomicrons play a role in the delivery of 
lipids to the bone marrow and spleen as a source of energy and for membrane biosynthesis 
or in the delivery of fat soluble vitamins. In addition, bone marrow macrophages, which are 
associated with erythroblasts in a hematopoietic environment, participate in erythropoiesis 
control, and engulfment of nuclei from erythroid precursor cells (Chasis & Mohandas, 2008; 
Qiu et al., 1995; Sadahira & Mori, 1999; Winkler et al., 2010; Yoshida et al., 2005). These 
features of bone marrow for uptake of senescent blood cells, lipoproteins, and nuclei can be 
original models of the specific bone marrow targeting system. 
The molecular mechanism of the uptake of lipid particles such as lipoproteins and apoptotic 
cells plays an important role in the transport and metabolism of fats such as cholesterol, 
triglycerides, and phospholipids. The attractive matter on the molecular mechanism is the 
ligand-receptor system, which permits the specific interaction of the lipid particles with 
specific cells in organs. For example, low-density lipoprotein (LDL), a native lipid particles 
consisting with cholesterol, ApoB-100, phospholipids, and lipophilic vitamins functions to 
transport cholesterol and vitamins from liver to peripheral tissues. LDL receptors on cells 
are responsible to the binding and following endocytosis of the LDL where ApoB-100 and 
ApoE on the LDL act as ligands to the LDL receptors. However, once the LDL is oxidized, 
scavenger receptors, instead of LDL receptors, act to recognize the oxidized LDL (OxLDL) 
where ApoB-100 and ApoE are not ligands to the scavenger receptors. Scavenger receptors 
are typically expressing on the mononuclear phagocyte cells including macrophages, 
monocytes, and endothelial cells. 
It is believed that OxLDL specifically expresses carboxyl groups on its surface and that 
scavenger receptors bind to the OxLDL via the carboxyl groups as ligands. 
Phosphatidylserine (PS), a characteristic phospholipid with a carboxyl group on its 
hydrophilic head group, is a known component of bilayer membrane and is asymmetrically 
localized in the intracellular membrane of living cells. However, PS is detected specifically 
on the surface of apoptotic cells that are detectable by the specific binding of annexin V to PS 
(Koopman et al., 1994; Martinet al., 1995). Consequently, it can be assumed that the 
asymmetry of the bilayer membrane disappears on the apoptosis of cells and that PS is 
exposed on the cell surface by the flip-flop. In addition, previous reports describe that the PS 
is detected on the activated platelets (Thiagarajan & Tait, 1990), senescent erythrocytes 
(Schroit & Zwaal, 1991), and nuclei from erythroblasts (Yoshida et al., 2005). A specific 
receptor to PS has been identified on the phagocytes, enabling phagocytes to recognize the 
biomembrane exposing PS and to eliminate it (Fadok et al., 1992, 2000). 
In selective elimination of lipid particles, oxidation of the unsaturated phospholipids plays a 
critical role. Natural phospholipids have polyunsaturated fatty acids such as linoleic acid 
and arachidonic acid. These polyunsaturated fatty acids are susceptible to free radical-
initiated oxidation. The general process of lipid peroxidation consists of three stages: 
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initiation, propagation, and termination (Catala, 2006). The initiation phase of lipid 
peroxidation includes hydrogen atom abstraction by which radicals such as hydroxyl (OH) 
react with polyunsaturated fatty acids to produce a lipid radical (L), which in turn reacts 
with molecular oxygen to form a lipid peroxyl radical (LOO). The LOO can abstract 
hydrogen from an adjacent fatty acid to produce a lipid hydroperoxide (LOOH) and a 
second lipid radical (Catala, 2006). The LOOH thus formed can suffer reductive cleavage by 
reduced metals such as Fe2+, producing a lipid alkoxyl radical (LO). Both alkoxyl and 
peroxyl radicals stimulate the chain reaction of lipid peroxidation by abstracting additional 
hydrogen atoms (Buettner, 1993). Finally, the decomposition of the alkoxyl radical produces 
a terminal carboxyl group. Several kinds of oxidized phospholipids having the terminal 
carboxyl group have been identified. These oxidized phospholipids are known as ligands or 
strong agonists to the scavenger receptors, especially CD36 (Gao et al., 2010; Podrez et al., 
2002). Further study has indicated that the carboxyl group of oxidized phospholipid is not 
located in the bilayer membrane but that it extends from the cellular surface like whiskers, 
in the “Whisker model”, to interact with the receptors (Greenberg et al., 2008; Hazen, 2008). 
This whisker model is expected to be important to design of surface of the drug delivery 
carrier, which is expected to interact with the receptors. 
 
Figure 1. Bone marrow in blood cell turnover. Bone marrow can be regarded as a cell culture system in 
which nutrients for hematopoiesis can be supplied from circulating blood as senescent cells, apoptotic 
cells, lipoproteins, and so on. The blood cell turnover in an adult human is 20–200×109/day which is 
estimated from the life time and total number of cells of each type. The image shows a hematoxylin and 
eosin stained rabbit bone marrow tissue section, where nuclei of hematopoietic cells are stained darkly 
and the circular blanks are adipocytes. 
3. Engineered carriers for bone marrow targeting 
Intravenous injected nano-sized materials are typically eliminated from blood circulation 
through a mononuclear phagocyte system (MPS). The main organs for uptake of the nano-
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sized materials are the liver and spleen in general. Little attention has been given to the bone 
marrow though the bone marrow is a part of MPS because the contribution of the bone 
marrow for uptake of nano-sized materials is believed to be small compared with those of 
the liver and spleen. However, results of several studies have shown that bone marrow is 
the most important organ for the uptake of nanoparticles that have been modified with 
specific molecules on their surface as presented in Table 1. 
 
Carrier type Targeting Target cells Species Ref 
Liposome Passive  
(Reduced size) 
Macrophages Dog Schettini et al., 
2006 
Liposome Active 
(Succinic acid-lipid) and 
passive (PEG-DSPE) 
Macrophages Monkey, 
Rabbit, 
Hamster 
Sou et al., 2007; 
2010; 2011a 
Polystyrene 
microspheres 
Active 
(Poloxamer 407) 
Endothelial cells Rabbit Porter et al., 1992; 
Moghimi, 1995 
Polymer complex Active  
(Cationic peptide) 
Monocytes, T-cell 
lineage cells 
Mouse Harris et al., 2010 
Porous silicon 
particles 
Active  
(E-selectin thioaptamer 
ligand) 
Endothelium 
 
Mouse Mann et al., 2011 
Nanoparticlesof 
dendritic 
molecule 
Active  
(Guanidinium group) 
Osteoclast 
precursors  
in vitro Chi et al., 2010 
Branched 
polypeptide 
Active  
(Succinyl group) 
Macrophages in vitro Szabó et al., 2005 
Table 1. Proposed drug delivery carriers targeting bone marrow. These carriers based on surface-
modified nanoparticles or polymers target bone marrow phagocytes such as macrophages and 
endothelial cells. 
3.1. Liposomes 
Liposomes are the most studied nanoparticles for drug and gene delivery to date. Great 
interest has been devoted to interaction between liposomes and cellular components in vitro 
and in vivo. Allen et al. studied the uptake of liposomes by cultured mouse bone marrow 
macrophages as a function of liposome composition (Allen et al., 1991). In this study, surface 
modification with monosialoganglioside (GM1) and polyethylene glycol-lipid (PEG-PE) 
greatly decreased DPPC liposome uptake by bone marrow macrophages in a concentration-
dependent manner. However, incorporation of PS increased liposome uptake by 
macrophages substantially in a concentration-dependent manner. These observations were 
correlated with the in vivo behavior of liposomes. Consequently, results of this study 
showed that liposome uptake by bone marrow macrophages is sensitive to the liposome 
composition, and that PS, which is a biological marker of apoptotic cells, accelerates the 
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uptake of the liposomes. Several other studies have also shown the accelerated uptake of 
liposomes containing PS or oxidized PS by macrophages, suggesting a similar molecular 
mechanism on apoptotic cell clearance (Fadok et al., 1992; Greenberg et al., 2006; Ishimoto et 
al., 2000). 
Schettini and co-workers prepared a novel liposomal formulation of meglumine 
antimoniate, a drug used for treating leishmaniasis, to deliver the drug to the bone marrow 
(Schettini et al., 2006). The liposomes were produced from distearoylphosphatidylcholine 
(DSPC), cholesterol, and dicetylphosphate (molar ratio of 5:4:1). The targeting of antimony 
to the bone marrow was improved approximately three-fold with the small liposomal 
formulation compared to the large liposome formulation used in dogs with visceral 
leishmaniasis. These liposomes had no active targeting factor to bone marrow, but the 
passive targeting of the liposomes to the bone marrow of dogs was improved by the 
reduction of vesicle size from 1200 nm to 400 nm. 
 
Figure 2. Lipid components of bone marrow-targeted lipid-based nanoparticles. Liposomes composed 
by DPPC, cholesterol and SA-lipid have high encapsulation capacity for water-soluble materials (Sou 
2011b). Oil-in-water (O/W) emulsions have advantage in embedding lipophilic drugs in their oil core. 
The uptake of lipid-based nanoparticles by bone marrow phagocytes in rhesus monkeys, rabbits, and 
hamsters is induced by the incorporation of SA-lipid. PEG-DSPE enhances the uptake of the 
nanoparticles by bone marrow phagocytes passively by preventing the uptake by hepatic and splenic 
phagocytes (Sou et al. 2007; 2010; 2011a).  
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Sou et al. found a liposome formulation that is specifically distributed to bone marrow in rabbits 
and rhesus monkeys (Sou et al., 2007, 2010, 2011a). Figure 2 shows that the bone marrow-
targeted liposomes comprise lipids of four kinds: 1,2-dipalmitoyl-sn-glycero-3- phosphocholine 
(DPPC), cholesterol, L-glutamic acid, N-(3-carboxy-1-oxopropyl)-, 1,5-dihexadecyl ester (SA-
lipid), and poly(ethylene glycol) (PEG). The SA-lipid component has been identified as the active 
factor leading to their phagocytosis by bone marrow phagocytes, presumably macrophages in 
rabbits (Sou et al., 2007). Furthermore, as little as 0.6 mol% of PEG-DSPE depressed hepatic 
uptake but did not depress the bone marrow uptake. PEG-DSPE can be incorporated into the 
outer surface of preformed liposomes using the post incorporation method (Sou et al., 2000; Uster 
et al., 1996). Otherwise PEG-DSPE is mixed with other lipid components before preparation of 
liposomes. The active targeting factor of SA-lipid and passive targeting factor of PEG-DSPE 
appear to increase the distribution of the liposomes to bone marrow cooperatively.  
 
Figure 3. Imaging analysis of animal receiving technetium-99m (99mTc)-labeled bone marrow-targeted 
liposomes. (A) Preformed liposomes encapsulated glutathione (GSH) can be radiolabeled with 99mTc by 
a remote loading method (Phillips et al., 1992). (B) Gamma camera images of rabbits acquired at 10 
minutes and 6 hours after injection of 99mTc-labeled bone marrow-targeted liposomes (Sou et al., 2007). 
The size of the liposomes between 200–270 nm is not a significant factor for uptake by bone 
marrow. The liposomes were designed to have high entrapment capacity with the interfacial 
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electrostatic interaction to form a unilamellar membrane (Sato et al., 2009; Sou et al., 2003; 
Sou 2011b). These characteristics are expected to facilitate the application of the bone 
marrow-targeted liposomes as pharmaceutical carriers to bone marrow. 
To evaluate the bone marrow-targeting capability quantitatively, whole body scintigraphic 
imaging in living animals is a particularly powerful tool (Goins and Phillips 2001, Phillips et 
al., 2009, 2011). Technetium-99m (99mTc), which is a good tracer for imaging, is used widely 
for single photon emission computed tomography with a gamma camera. Figure 3A shows 
that the 99mTc labeling of the liposomes encapsulating glutathione (GSH) can be 
accomplished using a complex of the 99mTc and GSH in inner aqueous phase of the 
liposomes (Phillips et al., 1992). Stoichiometric analysis has shown a 2:1 molar ratio of GSH 
and 99mTc for stable complex formation (Baba et al., 1999). Images presented in Figure 3B 
show the distribution of 99mTc-labeled bone marrow-targeted liposomes in a rabbit at 10 min 
and 6 hr after intravenous injection (lipid dose: 15 mg/kg b.w.). The image at 10 min is a 
typical blood pool image representing large blood pool at heart and liver, where the 
liposomes exist in blood circulation. At 6 hr, the radioactivity at the bone including marrow 
is increased, although it is decreased at the heart and liver. At this point, 69.7±0.3%ID of 
bone marrow-targeted liposomes accumulated in bone marrow. At the same time point, the 
liver and spleen respectively contained much smaller amounts of 11.5±2.88 and 5.0±1.19%ID 
(Sou et al., 2007). 
In addition to the macroscopic and quantitative observation of the distribution of the 
liposomes by scintigraphic imaging, histological observation by microscopic techniques 
enables further microscopic localization of the liposomes in bone marrow tissues. 
Transmission electron microscopy (TEM) is the frequent method used to observe the 
nanoparticle sample to determine their size and size distribution. Observations of liposomes 
in cells and tissues can be made using TEM (Sakai et al., 2001). Figure 4 shows that 
microscopic localization studies demonstrate that bone marrow macrophages are the 
cellular components responsible for clearance of bone marrow-targeted liposomes from 
circulation and that they are also responsible for their uptake by the bone marrow. The 
liposomes are located in the phagosomes and lysosomes of bone marrow macrophages, 
indicating that the bone marrow macrophages capture the liposomes through phagocytosis. 
Therefore, it can be speculated that bone marrow-targeted liposomes interact with a 
receptor on the bone marrow macrophages, which stimulates the phagocytic activity of bone 
marrow macrophages specifically.  
Also flow cytometry analysis is a useful method to determine the targeted cell population 
quantitatively (Harris et al., 2010). In this method, bone marrow cells will be labeled with 
markers to identify specific cell subtypes. Flow cytometry analysis might be particularly 
useful for animal experiment in mice and rats because the markers to identify specific cell 
subtypes are extensive for these species. Other possible method to identify the cell type is 
the immunofluorescent staining. The cells type emitting fluorescence from nanoparticle 
carriers or cargos in tissue section could be determined from the comparative analysis with 
images of immunofluorescent staining (Longmuir et al., 2009). 
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Figure 4. Transmission electron microscopic observations of bone marrow-targeted liposomes. (A) 
Bone marrow macrophages in a femoral bone marrow tissue section, taken from rabbit. Many 
phagosomes and lysosomes (electron-dense vacuoles) are visible. (B) Bone marrow macrophages in a 
femoral bone marrow tissue section, taken from a rabbit at 6 hr after intravenous injection of bone 
marrow-targeted liposomes (lipids: 15 mg/kg b.w.). Arrows indicate phagosome maturations trapping 
liposomes with the original diameter (average 270 nm) (Sou et al., 2007). MN: macrophage nucleus 
Fluorescent techniques enable detection of the distribution of particular components labeled 
with fluorescent probes in live cells and tissues microscopically, with exquisite sensitivity 
and selectivity. For liposomes, both the lipid bilayer membrane (green fluorescent C1-
BODIPY C12) and inner aqueous phase (red fluorescent Texas Red- superoxide dismutase, 
TR-SOD) were labeled with fluorescence probes as shown in Figure 5A. At 6 hr after 
injection of the dual-labeled bone marrow-targeted liposomes in rabbits (lipids: 15 mg/kg 
b.w.), the femoral bone marrow section was observed using confocal scanning microscopy. 
Figure 5B shows that the bone marrow sections have fluorescence from both the TR-SOD 
and C1-BODIPY C12, where the fluorescence from membrane probes and encapsulated 
probes are co-localized in bone marrow. This observation revealed that the bone marrow-
targeted liposomes and encapsulated agents are distributed at the same locations into bone 
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marrow tissues, clearly indicating that the encapsulated agents were delivered to bone 
marrow tissues by the liposomes. 
 
Figure 5. Histological examination of fluorescence delivered into bone marrow tissues using bone 
marrow-targeted liposomes as carriers. (A) Fluorescence localization in double fluorescence-labeled 
large multilamellar bone marrow-targeted liposomes with ca. 10 mm diameter. (B) Confocal scanning 
images of femoral bone marrow taken from a rabbit at 6 hr after i.v. injection of double fluorescence-
labeled bone marrow-targeted liposomes (lipids: 15 mg/kg b.w.) (Sou et al., 2007). Scale bars show 20 
μm. 
3.2. Polymeric nanoparticles 
Regarding engineered colloidal particles, Porter and co-workers observed remarkable 
accumulation of small colloidal particulates (150 nm and smaller diameter) that were coated 
by the block co-polymer poloxamer-407, a non-ionic surfactant, in the bone marrow after 
intravenous administration in rabbits (Porter et al., 1992). In this case, the coated colloids 
were sequestered by the sinusoidal endothelial cells of the bone marrow instead of 
macrophages. Importantly, no marked uptake was achievable with other block co-polymers 
having a similar structure to that of poloxamer-407, suggesting the participation of a specific 
interaction mechanism between the particle and the sinusoidal endothelial cell surface. 
Chi and co-workers prepared dendritic amine and guanidinium group-modified 
nanoparticles for the delivery of model peptide drug into primary osteoclast precursor cells 
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(bone marrow macrophages) (Chi et al., 2010). It can be speculated that positively charged 
guanidinium groups have favorable interactions with negatively charged functional groups 
in the cell membrane of osteoclast precursors (Rothbard et al., 2005). Physicochemical 
interaction between a positively charged drug carrier and a negatively charged cell surface 
can enhance the cellular uptake in cells of various kinds with a negatively charged surface. 
However, the selectivity to specific bone marrow cells might be low in practical applications 
for drug delivery carriers. 
Harris and co-workers studied tissue-specific gene delivery via nanoparticle coating (Harris 
et al., 2010). They prepared cationic nanoparticles with plasmid DNA and then coated their 
cationic surface with poly anionic poly(glutamic acid)-based peptides with and without 
cationic insert. Particles coated with a low 2.5:1 peptide:DNA weight ratio (w/w) form two 
large micro-sized particles that can facilitate specific gene delivery to the liver in mice. 
However, the same particles coated at a higher 20:1 peptide with cationic insert:DNA (w/w) 
form small 200 nm particles that can facilitate specific gene delivery to the spleen and bone 
marrow. They have confirmed that the terminal sequence insert, cationic amino acid 
sequence G-dP-dL-G-dV-dR-G, to the poly(glutamic acid)-based peptides is a critical factor 
enhancing bone marrow and spleen-specificity of gene delivery in vivo. Regions of 
luminescence selected around the femur bones showed nearly 40-fold enhancement, and 
regions around the spleen showed nearly 30-fold enhancement by the cationic insert. Flow 
cytometry analysis of bone marrow cells from a mouse tail-vein injected with green 
fluorescent protein-encoding nanoparticles coated with 20:1 w/w peptide with a cationic 
insert revealed that green fluorescent protein expression relative to the whole population of 
bone marrow cells is enriched in monocyte and T-cell lineage cells. This system might be 
available for bone marrow-specific drug delivery and for gene delivery. The molecular 
mechanism at work in this system is not obvious. 
E-selectin is an attractive molecular target for active targeting of a drug carrier to bone marrow 
because E-selectin is expressed selectively on endothelial cells of adult and fetal hematopoietic 
organs (Schweitzer et al., 1996). It has been suggested that the E-selectin plays a role in the 
homing of hematopoietic progenitor cells and that its constitutive expression on endothelial 
cells of hematopoietic organs is necessary in the initial step of the homing process. Mann and 
co-workers identified a thiophosphate-modified aptamer (thioaptamer) against E-selectin 
(Mann et al., 2010). They confirmed that the thioaptamer ligand selectively binds to E-selectin 
with nanomolar binding affinity (KD=47 nM) while exhibiting minimal cross reactivity to P-
selectin and L-selectin. Recently, they developed porous silicon particles modified with E-
selectin thioaptamer ligands to target bone marrow endothelium (Mann et al., 2011). A mice 
study demonstrated that the accumulation of the porous silicon particles modified with E-
selectin thioaptamer ligands in the bone marrow was eight times higher than control porous 
silicon particles, which were accumulated primarily in the liver and spleen instead of bone 
marrow. Histological analysis supported the presence of porous silicon particles modified 
with E-selectin thioaptamer ligands on the endothelial wall of the bone marrow tissue. The 
molecular target of this ligand-receptor reaction might be readily apparent in this system and 
be promising for delivering drugs to bone marrow endothelial cells specifically. 
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Moghimi reviewed the clearance mechanism of particulate materials from the circulation by 
bone marrow (Moghimi, 1995). The endothelium of bone marrow sinusoids can remove 
particles from circulation by both transcellular and intercellular routes. The intercellular route 
occurs through the fenestrate in the endothelial wall. Therefore this mechanism is strongly 
dependent on the particle size. The intercellular distance is less than 2 nm for the tight junctions 
in capillaries and less than 6 nm for post-capillary venules under normal conditions 
(Simionescu et al., 1978; Bundgaard, 1980). In contrast, the size of the fenestrate in the 
endothelial wall is reportedly 85–150 nm (Huang, 1971). These fenestrated capillaries exist in 
bone marrow as well as in the liver and spleen. Therefore, the intercellular route is a possible 
pathway to target bone marrow through circulation. Liposomes consisting of DSPC, cholesterol, 
PEG(5000)-DSPE, and α-tocopherol prepared in various sizes (136–318 nm diameter) have been 
tested for organ distribution in rabbits. None of these liposomes show a significant 
accumulation in bone marrow (Awasthi et al., 2003). Therefore, the passive diffusion of 
nanoparticles from blood circulation to extravascular space through an intercellular route is not 
an important factor in bone marrow targeting when no active targeting factor exists. Indeed, 
based on the proposed drug delivery carrier described above, the surface modification of 
nanoparticles with specific molecules is a critical factor to achieve bone marrow targeting with 
nanoparticles, although further study is necessary to ascertain details of its molecular 
mechanism. Consequently, discovery of receptors specifically expressing in bone marrow 
tissues facilitates the development of drug carriers targeting bone marrow. 
4. Future prospects for bone-marrow-targeted drug carrier systems 
The balance between blood cell production and removal in blood cells of each type is 
important to maintain the number of circulating blood cells. When blood cell production is 
suppressed, erythrocytopenia, leukopenia, and thrombocytopenia are induced. The blood 
cell production suppression results from the direct bone marrow dysfunction or indirect 
factor such as deficiency of the hematopoietic growth factors such as erythropoietin (EPO), 
granulocyte colony-stimulation factor (G-CSF), and thrombopoietin (TPO). These 
hematopoietic growth factors, EPO and G-CSF, have been established as recombinant 
products. Recombinant EPO products are used clinically for the renal anemia patients or 
autologous blood. These growth factors function with hematopoietic cells in bone marrow, 
so that a drug delivery system to target bone marrow can be expected to offer an improved 
therapeutic system.  
Recently, Winkler and co-workers reported that the bone marrow macrophages are pivotal 
to maintain an endosteal hematopoietic stem cell niche and that the loss of such 
macrophages engenders the egress of hematopoietic stem cells into the blood (Winkler et al., 
2010). They administered clodronate-loaded liposomes intravenously to deplete the bone 
marrow macrophages. After the macrophage depletion, hematopoietic stem cells were 
found in the blood. These findings provide evidence supporting the critical role that 
macrophages play in the support of hematopoietic cells in bone marrow. Such specific 
biology of bone marrow macrophages can present a therapeutic target for the treatment of 
hematopoietic disorders. 
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Leishmaniasis is an infectious disease caused by a protozoan parasite that is parasitic on 
resident macrophages. Promastigotes, which are injected into the skin by a sandfly, are 
phagocytized by macrophages. Thereafter, promastigotes transform into amastigotes inside 
macrophages. The amastigotes multiply in cells, including in macrophages, at various 
tissues. The typical symptoms in leishmaniasis are damage to the spleen and liver, and 
anemia by damage to bone marrow. Therefore, macrophages in bone marrow as well as in 
the liver and spleen are target cells in leishmaniasis treatment. Thus several nanoparticles 
loaded with therapeutic agents such as nanoparticles loaded with amphotericin B (Gupta & 
Vyas 2007; Nahar et al., 2010 ), PLGA nanoparticles loaded with saponin (Van de Ven et al., 
2012), lipid nanoparticles loaded with oryzalin (Lopes et al., 2012), PLGA nanoparticles 
loaded with kinetoplastid membrane protein-11 (Santos et al., 2012) have been developed to 
deliver the drugs in leishmania-infected macrophages. Drug carriers targeting bone marrow, 
especially bone marrow macrophages, would have a great potential to deliver these 
therapeutic agents in leishmania-infected macrophages. 
The abnormal increase of cancerous cells such as leukemia cells, which are immature white 
blood cells in bone marrow, suppress normal hematopoiesis. Different from a solid cancer, 
surgical resection is ineffective as a treatment for leukemia. Most cases of leukemia are 
treated using chemotherapy. Therapies are typically combined into multi-drug 
chemotherapy. Drug delivery systems targeting bone marrow can increase the efficacy of 
such methods. Moreover, bone marrow is sensitive to chemotherapy and radiation therapy. 
Several pharmaceuticals are available to protect soft tissues from chemotherapy and 
irradiation. Drug carriers targeting bone marrow offer a promising platform to deliver such 
pharmaceuticals to bone marrow effectively. 
5. Conclusion 
Conventional drug delivery to bone marrow is uncontrolled passive diffusion of drugs into 
bone marrow through blood circulation. The fraction of drugs reaching the target site 
through such passive diffusion is negligibly small. Bone marrow-targeted drug delivery 
carriers provide a platform to develop more efficient and safer diagnostic and therapeutic 
systems. These therapeutic systems can target bone and bone marrow diseases such as 
rheumatoid arthritis, bone regeneration and repair, bone metastases, osteoporosis, infectious 
diseases, multiple myeloma, and hematopoietic dysfunction. 
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